Physician

Alan Ken Matsumoto, M.D.

According to 2025 Medicare claims, Alan Matsumoto, M.D. (NPI: 1043219298) practices rheumatology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Montgomery, MD. This provider's primary affiliated billing organization is ARTHRITIS AND RHEUMATISM ASSOCIATES PC (NPI: 1447259866; TIN: 521072944) and primary practice location at 20902-1990.

Matsumoto's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,266 traditional Medicare patients, billed 192,940 HCPCS/CPT codes, and received $3,752,966 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,372 prescription claims across 405 beneficiaries totaling $2,782,706 in drug costs, led by Enbrel Sureclick (Etanercept). 2023 DME data shows 22 claims. Open Payments data shows 97 records totaling $29,132. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $718,750 to $3,752,966. Similarly, Part D prescription costs have moved sharply higher in recent years, from $830,734 to $2,782,706. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	624	47,278	$718,750
2016	695	51,380	$1,033,657
2017	786	57,196	$1,283,984
2018	772	56,184	$1,437,477
2019	691	55,460	$1,200,022
2020	607	49,949	$1,006,203
2021	727	92,234	$1,858,233
2022	994	113,322	$1,741,525
2023	1,257	197,356	$3,539,276
2024	1,266	192,940	$3,752,966

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	237	1,909	$830,734
2016	256	1,698	$754,031
2017	254	1,770	$1,148,141
2018	274	1,855	$1,062,255
2019	285	1,918	$1,145,697
2020	264	1,748	$1,347,324
2021	275	1,776	$1,420,785
2022	335	1,966	$2,012,386
2023	329	1,998	$2,111,229
2024	405	2,372	$2,782,706

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$630
2021	N/R	N/R	N/R
2022	13	13	$921
2023	N/R	22	$1,860
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	578	1,183	$103
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	731	1,421	$13
80053	Blood test, comprehensive group of blood chemicals	464	926	$10
36415	Insertion of needle into vein for collection of blood sample	467	722	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	455	916	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	88	2,800	$737,213
Humira(Cf) Pen	Adalimumab	49	1,988	$541,353
Enbrel	Etanercept	25	1,204	$321,481
Rinvoq	Upadacitinib	32	1,500	$321,335
Humira Pen	Adalimumab	13	588	$134,038

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$27,615	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$1,517	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Ken Matsumoto, M.D.?

Tedicare shows public-source Medicare data for Alan Ken Matsumoto, M.D. (NPI 1043219298), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Ken Matsumoto, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan Ken Matsumoto, M.D.?

Alan Ken Matsumoto, M.D. is linked to ARTHRITIS AND RHEUMATISM ASSOCIATES PC (billing NPI 1447259866) in the available physician profile data.

Does Alan Ken Matsumoto, M.D. have Open Payments data?

Alan Ken Matsumoto, M.D. has 97 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.